The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aratana Therapeutics Inc. Common 03874P101 7,065 1,117,875 SH   SOLE   1,117,875 0 0
Chiasma, Inc. Common 16706W102 16,578 5,736,296 SH   SOLE   5,736,296 0 0
CoLucid Pharmaceuticals, Inc. Common 19716T101 178 21,806 SH   SOLE   21,806 0 0
Conatus Pharmaceuticals, Inc. Common 20600T108 2,456 1,192,080 SH   SOLE   1,192,080 0 0
Endologix, Inc. Common 29266S106 13,973 1,121,447 SH   SOLE   1,121,447 0 0
EnteroMedics, Inc. Common 29365M307 22 74,215 SH   SOLE   74,215 0 0
EpiZyme, Inc. Common 29428V104 17,712 1,729,674 SH   SOLE   1,729,674 0 0
MacroGenics, Inc. Common 556099109 86 3,168 SH   SOLE   3,168 0 0
Mast Therapeutics, Inc. Common 576314108 1,199 2,551,851 SH   SOLE   2,551,851 0 0
Nevro Corporation Common 64157F103 5,341 72,413 SH   SOLE   72,413 0 0
Proteon Therapeutics, Inc. Common 74371L109 7,897 983,381 SH   SOLE   983,381 0 0
Radius Health, Inc. Common 750469207 214,299 5,831,253 SH   SOLE   5,831,253 0 0
Sangamo Biosciences, Inc. Common 800677106 130 22,487 SH   SOLE   22,487 0 0
Syndax Pharmaceuticals, Inc. Common 87164F105 21,362 2,168,691 SH   SOLE   2,168,691 0 0